Stock Scorecard
Stock Summary for ARS Pharmaceuticals Inc (SPRY) - $10.15 as of 12/15/2025 9:15:04 AM EST
Total Score
10 out of 30
Safety Score
38 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SPRY
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SPRY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SPRY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SPRY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SPRY (38 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for SPRY
Financial Details for SPRY
Company Overview |
|
|---|---|
| Ticker | SPRY |
| Company Name | ARS Pharmaceuticals Inc |
| Country | USA |
| Description | ARS Pharmaceuticals, Inc. (SPRY) is a cutting-edge biopharmaceutical company headquartered in San Diego, California, dedicated to the development of ARS-1, an innovative intranasal epinephrine aerosol. This product is designed to deliver rapid relief for individuals facing life-threatening allergic reactions, utilizing proprietary absorption technology to enhance accessibility and ease of use. With a strong commitment to addressing pressing public health challenges, ARS Pharmaceuticals seeks to transform allergy management and establish itself as a leader in the allergy treatment market. The company's focus on patient-centric solutions underscores its potential for significant impact within the healthcare sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 10.15 |
| Price 4 Years Ago | 6.66 |
| Last Day Price Updated | 12/15/2025 9:15:04 AM EST |
| Last Day Volume | 2,133,660 |
| Average Daily Volume | 2,243,884 |
| 52-Week High | 18.90 |
| 52-Week Low | 6.66 |
| Last Price to 52 Week Low | 52.40% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 24.28 |
| Sector PE | 107.71 |
| 5-Year Average PE | 24.30 |
| Free Cash Flow Ratio | 16.92 |
| Industry Free Cash Flow Ratio | 17.33 |
| Sector Free Cash Flow Ratio | 23.05 |
| Current Ratio Most Recent Quarter | 6.66 |
| Total Cash Per Share | 0.60 |
| Book Value Per Share Most Recent Quarter | 1.49 |
| Price to Book Ratio | 6.86 |
| Industry Price to Book Ratio | 50.12 |
| Sector Price to Book Ratio | 21.81 |
| Price to Sales Ratio Twelve Trailing Months | 7.33 |
| Industry Price to Sales Ratio Twelve Trailing Months | 24.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.58 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 98,849,000 |
| Market Capitalization | 1,003,317,350 |
| Institutional Ownership | 87.30% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 114.71% |
| Reported EPS 12 Trailing Months | -0.81 |
| Reported EPS Past Year | -1.33 |
| Reported EPS Prior Year | 0.07 |
| Net Income Twelve Trailing Months | -80,040,000 |
| Net Income Past Year | 7,998,000 |
| Net Income Prior Year | -54,365,000 |
| Quarterly Revenue Growth YOY | 1,472.00% |
| 5-Year Revenue Growth | -46.80% |
| Operating Margin Twelve Trailing Months | -163.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 59,557,000 |
| Total Cash Past Year | 50,817,000 |
| Total Cash Prior Year | 70,971,000 |
| Net Cash Position Most Recent Quarter | -36,672,000 |
| Net Cash Position Past Year | 50,817,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 8,409,000 |
| Total Debt Most Recent Quarter | 96,229,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.61 |
| Total Stockholder Equity Past Year | 256,798,000 |
| Total Stockholder Equity Prior Year | 230,760,000 |
| Total Stockholder Equity Most Recent Quarter | 147,655,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -86,018,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.87 |
| Free Cash Flow Past Year | 12,985,000 |
| Free Cash Flow Prior Year | -59,441,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.03 |
| MACD Signal | -0.30 |
| 20-Day Bollinger Lower Band | 5.19 |
| 20-Day Bollinger Middle Band | 11.29 |
| 20-Day Bollinger Upper Band | 17.39 |
| Beta | 0.80 |
| RSI | 55.48 |
| 50-Day SMA | 12.75 |
| 150-Day SMA | 9.90 |
| 200-Day SMA | 8.65 |
System |
|
| Modified | 12/16/2025 8:49:58 AM EST |